We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
Cap. Flow
-$415M
Cap. Flow %
-21.46%
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30

Top Buys

Rank Stock Value
1
GMAB icon
Genmab
GMAB
+$87.5M
2
SPTX
Seaport Therapeutics
SPTX
+$62.7M
3
GILD icon
Gilead Sciences
GILD
+$45.2M
4
ANAB icon
AnaptysBio
ANAB
+$14.9M
5
ABT icon
Abbott
ABT
+$11.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$89.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$63.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$51M
4
UTHR icon
United Therapeutics
UTHR
+$47.1M
5
BIIB icon
Biogen
BIIB
+$42.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.78%
2 Miscellaneous 3.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
76
Vaxcyte
PCVX
$8.86B
– –
-50,600
Closed -$2.94M
PFE icon
77
CALL
Pfizer
PFE
$158B
– –
-800,000
Closed -$22.5M
QQQ icon
78
PUT
Invesco QQQ Trust
QQQ
$489B
– –
-150,000
Closed -$86.6M
REPL icon
79
CALL
Replimune Group
REPL
$1.36B
– –
-1,015,400
Closed -$7.77M
ROIV icon
80
Roivant Sciences
ROIV
$30.2B
– –
-477,995
Closed -$13.2M
SLNO
81
DELISTED
Soleno Therapeutics
SLNO
– –
-14,689
Closed -$492K
SYK icon
82
Stryker
SYK
$106B
– –
-44,480
Closed -$14.6M
TNGX icon
83
Tango Therapeutics
TNGX
$4.05B
– –
-395,081
Closed -$8.27M
UTHR icon
84
PUT
United Therapeutics
UTHR
$21.7B
– –
-80,300
Closed -$47.6M
XBI icon
85
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.1B
– –
-1,050,000
Closed -$134M
XENE icon
86
Xenon Pharmaceuticals
XENE
$5.71B
– –
-305,216
Closed -$17.7M
ZYME icon
87
Zymeworks
ZYME
$1.94B
– –
-1,610
Closed -$40.3K
1 2 3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q2 2026 Portfolio in Review

As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.

  • Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
  • Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
  • Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
  • Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
  • Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
  • Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.